Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXP018
- Development stage
- Preclinical
- Lead developer
- Excalipoint Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
EXP018 is a masked or probody T-cell engager (Pro-TCE) in development by Excalipoint Therapeutics for the treatment of solid tumors. Developed using the company's proprietary EXPROMA™ (TCE Probody) platform, EXP018 is designed to conditionally engage T cells within the tumor microenvironment, thereby minimizing systemic toxicity and off-target effects. The specific tumor-associated antigen targeted by EXP018 remains undisclosed.
Beyond the preview
Go deeper on EXP018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXP018.